HK1215674A1 - 结合使用莫米松和奥洛他定治疗过敏性鼻炎 - Google Patents

结合使用莫米松和奥洛他定治疗过敏性鼻炎 Download PDF

Info

Publication number
HK1215674A1
HK1215674A1 HK16103630.2A HK16103630A HK1215674A1 HK 1215674 A1 HK1215674 A1 HK 1215674A1 HK 16103630 A HK16103630 A HK 16103630A HK 1215674 A1 HK1215674 A1 HK 1215674A1
Authority
HK
Hong Kong
Prior art keywords
olopatadine
mometasone
combination
allergic rhinitis
treatment
Prior art date
Application number
HK16103630.2A
Other languages
English (en)
Chinese (zh)
Inventor
Neelima Khairatkar Joshi
Abhay Kulkarni
Dinesh Pradeep WALE
Vikram Mansingh BHOSALE
Piyush Agarwal
Patrick Keohane
Sudeesh K. TANTRY
Chad OH
Original Assignee
Glenmark Pharmaceuticals Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glenmark Pharmaceuticals Limited filed Critical Glenmark Pharmaceuticals Limited
Publication of HK1215674A1 publication Critical patent/HK1215674A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/44—Glucocorticosteroids; Drugs increasing or potentiating the activity of glucocorticosteroids

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Endocrinology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
HK16103630.2A 2013-10-04 2014-10-03 结合使用莫米松和奥洛他定治疗过敏性鼻炎 HK1215674A1 (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
INMM31742013 2013-10-04
IN3174MU2013 2013-10-04
PCT/IB2014/065035 WO2015049665A1 (en) 2013-10-04 2014-10-03 Treatment of allergic rhinitis using a combination of mometasone and olopatadine

Publications (1)

Publication Number Publication Date
HK1215674A1 true HK1215674A1 (zh) 2016-09-09

Family

ID=51982657

Family Applications (1)

Application Number Title Priority Date Filing Date
HK16103630.2A HK1215674A1 (zh) 2013-10-04 2014-10-03 结合使用莫米松和奥洛他定治疗过敏性鼻炎

Country Status (12)

Country Link
US (1) US10646500B2 (enExample)
EP (2) EP2922553A1 (enExample)
JP (3) JP6419195B2 (enExample)
CN (2) CN112773808A (enExample)
HK (1) HK1215674A1 (enExample)
MX (2) MX2015009429A (enExample)
MY (1) MY176808A (enExample)
PH (1) PH12015502302B1 (enExample)
RU (1) RU2686670C2 (enExample)
UA (1) UA120587C2 (enExample)
WO (1) WO2015049665A1 (enExample)
ZA (1) ZA201504740B (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9370483B2 (en) 2013-09-13 2016-06-21 Glenmark Specialty S.A. Stable fixed dose pharmaceutical composition comprising mometasone and olopatadine
US9937189B2 (en) 2013-09-13 2018-04-10 Glenmark Specialty S.A. Stable fixed dose pharmaceutical composition comprising mometasone and olopatadine
EP2922553A1 (en) * 2013-10-04 2015-09-30 Glenmark Pharmaceuticals Limited Treatment of allergic rhinitis using a combination of mometasone and olopatadine
US10758550B2 (en) 2013-10-04 2020-09-01 Glenmark Specialty S.A. Treatment of allergic rhinitis using a combination of mometasone and olopatadine
US10653661B2 (en) 2013-10-04 2020-05-19 Glenmark Specialty S.A. Treatment of allergic rhinitis using a combination of mometasone and olopatadine
US10548907B2 (en) 2013-10-04 2020-02-04 Glenmark Specialty S.A. Treatment of allergic rhinitis using a combination of mometasone and olopatadine
US10016443B2 (en) 2013-10-04 2018-07-10 Glenmark Specialty S.A. Treatment of allergic rhinitis using a combination of mometasone and olopatadine
US11679210B2 (en) 2014-10-03 2023-06-20 Glenmark Specialty S.A. Dispensing device and pharmaceutical composition for the treatment of rhinitis
DK3468532T3 (da) * 2017-06-28 2021-01-04 Glenmark Specialty Sa Dispenseranordning og farmaceutisk sammensætning til behandling af rhinitis
AU2019224850B2 (en) * 2018-02-23 2024-11-28 Glenmark Specialty S.A. Treatment of allergic rhinitis in pediatric subjects using a combination of mometasone and olopatadine
US12303635B2 (en) 2018-04-16 2025-05-20 Glenmark Specialty S.A. Dispensing device and pharmaceutical composition for the treatment of rhinitis

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4923892A (en) 1985-08-17 1990-05-08 Burroughs Wellcome Co. Tricyclic aromatic compounds
GB8520662D0 (en) 1985-08-17 1985-09-25 Wellcome Found Tricyclic aromatic compounds
US6127353A (en) 1991-09-06 2000-10-03 Schering Corporation Mometasone furoate monohydrate, process for making same and pharmaceutical compositions
PE44995A1 (es) 1994-01-27 1995-12-18 Schering Corp Furoato de mometasona para el tratamiento de las enfermedades pulmonares y de las vias respiratorias
US5837699A (en) * 1994-01-27 1998-11-17 Schering Corporation Use of mometasone furoate for treating upper airway passage diseases
EP1227812B1 (en) 1999-10-08 2007-04-18 Schering Corporation Topical nasal treatment using desloratadine and mometasone furoate
US7977376B2 (en) 2001-06-27 2011-07-12 Novartis Ag Olopatadine formulations for topical nasal administration
JP2006508138A (ja) * 2002-11-12 2006-03-09 アルコン，インコーポレイテッド アレルギー性鼻炎を処置するための抗アレルギー剤およびステロイドの使用
US8912174B2 (en) 2003-04-16 2014-12-16 Mylan Pharmaceuticals Inc. Formulations and methods for treating rhinosinusitis
DK1814538T3 (da) 2004-11-24 2009-11-02 Alcon Inc Fremgangsmåde til administration af næsespray
EP1919450B1 (en) 2005-09-01 2014-06-11 Meda AB Antihistamine- and corticosteroid-containing liposome composition and its use for the manufacture of a medicament for treating rhinitis and related disorders
WO2007064912A2 (en) 2005-12-02 2007-06-07 Elan Pharma International Limited Mometasone compositions and methods of making and using the same
HUE036777T2 (hu) 2006-04-21 2018-07-30 Toko Yakuhin Kogyo Kk Bõrhöz/nyálkahártyához tapadó porlasztható gél típusú preparátum és adagolási rendszer a preparátum alkalmazásával
CN101795565A (zh) * 2007-06-28 2010-08-04 锡德克斯药物公司 皮质类固醇水溶液的鼻部和眼部给药
JP2011528355A (ja) 2008-07-15 2011-11-17 シェーリング コーポレイション 充血除去剤およびコルチコステロイドを含む鼻腔内粗製物
US8642069B2 (en) 2008-08-27 2014-02-04 Alexander D. Goldin Composition and method for treating colds
WO2011008923A2 (en) 2009-07-17 2011-01-20 Alcon Research, Ltd. Olopatadine nasal spray regimen for children
CN102078285A (zh) * 2009-11-26 2011-06-01 天津金耀集团有限公司 含有皮质激素和h1受体拮抗剂的鼻用原位凝胶
CN102078326A (zh) * 2009-11-26 2011-06-01 天津金耀集团有限公司 含有聚维酮碘与糠酸莫米松的局部使用组合物
WO2011141929A2 (en) 2010-05-11 2011-11-17 Cadila Healthcare Limited Aqueous pharmaceutical compositions of fluticasone and olopatadine
CN103269687B (zh) 2011-01-04 2016-09-14 伊斯塔制药公司 贝托斯汀组合物
MX2015005081A (es) 2012-10-25 2015-07-17 Novozymes As Metodo mejorado para el lavado manual de la vajilla.
KR20140081925A (ko) 2012-12-12 2014-07-02 한미약품 주식회사 코르티코스테로이드, 항히스타민제 및 스테비아를 포함하는 고미 차폐된 약학 제제
SMT202100563T1 (it) * 2013-09-13 2021-11-12 Glenmark Specialty Sa Composizione farmaceutica stabile a dose fissa comprendente mometasone e olopatadina per la somministrazione nasale
US9370483B2 (en) 2013-09-13 2016-06-21 Glenmark Specialty S.A. Stable fixed dose pharmaceutical composition comprising mometasone and olopatadine
EP2922553A1 (en) * 2013-10-04 2015-09-30 Glenmark Pharmaceuticals Limited Treatment of allergic rhinitis using a combination of mometasone and olopatadine

Also Published As

Publication number Publication date
RU2015128496A (ru) 2017-11-13
JP2018123157A (ja) 2018-08-09
JP2020097624A (ja) 2020-06-25
MX2015009429A (es) 2015-10-09
US10646500B2 (en) 2020-05-12
WO2015049665A1 (en) 2015-04-09
CN112773808A (zh) 2021-05-11
JP2016531949A (ja) 2016-10-13
JP6768733B2 (ja) 2020-10-14
RU2019104453A (ru) 2019-03-28
EP4272839A3 (en) 2024-01-03
EP4272839A2 (en) 2023-11-08
RU2015128496A3 (enExample) 2018-06-19
CN105792828A (zh) 2016-07-20
MY176808A (en) 2020-08-21
PH12015502302A1 (en) 2016-02-15
PH12015502302B1 (en) 2016-02-15
RU2686670C2 (ru) 2019-04-30
MX2020003035A (es) 2020-07-22
EP2922553A1 (en) 2015-09-30
US20150099725A1 (en) 2015-04-09
JP6419195B2 (ja) 2018-11-07
ZA201504740B (en) 2016-10-26
UA120587C2 (uk) 2020-01-10

Similar Documents

Publication Publication Date Title
HK1215674A1 (zh) 结合使用莫米松和奥洛他定治疗过敏性鼻炎
IL260585B (en) Compositions and methods for treating retinal diseases
IL238432A0 (en) Methods and devices for the treatment of ocular diseases in human subjects
EP3013407A4 (en) Medical treatment system and method of use
EP3071193A4 (en) Compositions and methods for treatment of ocular inflammation and pain
IL240169A0 (en) Pyrimidine compositions for use in the treatment of diseases affected by ikke or tbk1 mechanisms
EP3084000A4 (en) Method of diagnosis and treatment
HK1197159A1 (en) Pirfenidone and anti-fibrotic therapy in selected patients
EP2967523A4 (en) Tissue and vascular closure devices and methods of use thereof
PL3466425T3 (pl) Zastosowanie pochodnych glutarimidu w leczeniu chorób eozynofilowych
EA201600096A1 (ru) Бензил-1н-пиразол[3,4-b]пиридины и их применение
WO2015197193A3 (en) New use for jnk inhibitor molecules for treatment of various diseases
EP3086809A4 (en) Compositions and methods of treating ocular diseases
EP2970249A4 (en) Coumarin derivatives and methods of use in treating hyperproliferative diseases
EA201690997A1 (ru) Композиция для применения в лечении стойкого кашля
EP2978449A4 (en) Compositions and methods for the treatment or prevention of human immunodeficiency virus infection
EP3060259A4 (en) Methods of treating or preventing vascular diseases of the retina
EP3068316A4 (en) Devices, kits and methods relating to treatment of facet joints
EP3030274A4 (en) Method of treating peripheral artery diseases in lower limbs
WO2015084883A3 (en) Compositions and methods for treating osteoarthritis
EP3066077A4 (en) Treatment of cardiac remodeling and other heart conditions
GB201710822D0 (en) Methods and medical uses relating to the treatment of hypoglycaemia
EP3013425A4 (en) Treatment and diagnosis of ocular disease
ME03399B (me) DERIVATI 2-ARIL-4-HIDROKSI-1,3-TIAZOLA KORISNI KAO INHIBITORI TRPM8 U LEĆENJU NEURALGIJE, BOLA, COPD l ASTME
EP3062804A4 (en) Pain relief formulation and method of treatment